The rapid spread of the hyper-contagious Delta variant of the coronavirus, along with the increasing need for treatments for other critical diseases, ensures a continued growth trajectory for the biotech industry. Against this backdrop, the author of today’s article highlights three biotech stocks to consider based on the promising products in their pipelines and analyst expectations for them: all three have near-term upside potential of more than 170%. For these three stocks, CLICK HERE.
3 Biotech Stocks With Promising Product Pipelines And More Than 170% Near-Term Upside Potential
- by RobH